Skip to content

Study · Animal study (in vivo) · rat · 2014

4 results

A dose-response study of thymosin β4 for the treatment of acute stroke.

Morris DC, Cui Y, Cheung WL, Lu M, Zhang L, Zhang ZG, Chopp M

Journal of the neurological sciences10 Jul 2014Cited by 29 (Europe PMC)

PMID25060418 (opens in a new tab)PMCIDPMC4177939 (opens in a new tab)DOI10.1016/j.jns.2014.07.006 (opens in a new tab)PepBankPUB-25060418
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, Tβ4 at 2 mg/kg significantly improved neurological outcome from day 14, and the effect lasted to day 56.

    In plain wordsIn rats with stroke, a 2 mg/kg dose of Tβ4 improved recovery of nerve function compared with control.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseNeurological outcome at day 14 to day 56
    Study

    ratn = 10

    embolic middle cerebral artery occlusion (MCAo)
    Comparator
    Control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2 mg/kg · intraperitoneal · 5 doses: 24 h after MCAo, then every 3 daysAs given in this study (rat).

    Source sentences

    Summary
    Tβ4 significantly improved neurological outcome at dose of 2 and 12 mg/kg at day 14 and extended to day 56 (p-values <0.05).
    3 context sentences
    Summary · context
    Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo).
    Summary · context
    Rats were divided into 4 groups of 10 animals/group: control, 2, 12 and 18 mg/kg.
    Summary · context
    Tβ4 was administered intraperitoneally 24h after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, Tβ4 at 12 mg/kg significantly improved neurological outcome from day 14, and the effect lasted to day 56.

    In plain wordsIn rats with stroke, a 12 mg/kg dose of Tβ4 improved recovery of nerve function compared with control.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseNeurological outcome at day 14 to day 56
    Study

    ratn = 10

    embolic middle cerebral artery occlusion (MCAo)
    Comparator
    Control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    12 mg/kg · intraperitoneal · 5 doses: 24 h after MCAo, then every 3 daysAs given in this study (rat).

    Source sentences

    Summary
    Tβ4 significantly improved neurological outcome at dose of 2 and 12 mg/kg at day 14 and extended to day 56 (p-values <0.05).
    3 context sentences
    Summary · context
    Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo).
    Summary · context
    Rats were divided into 4 groups of 10 animals/group: control, 2, 12 and 18 mg/kg.
    Summary · context
    Tβ4 was administered intraperitoneally 24h after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, Tβ4 at 18 mg/kg did not show significant improvement in neurological outcome.

    In plain wordsIn rats with stroke, the highest dose of Tβ4 did not significantly improve recovery of nerve function.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeNeurological outcome
    Study

    ratn = 10

    embolic middle cerebral artery occlusion (MCAo)
    Comparator
    Control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    18 mg/kg · intraperitoneal · 5 doses: 24 h after MCAo, then every 3 daysAs given in this study (rat).

    Source sentences

    Summary
    The higher dose of 18 mg/kg did not show significant improvement.
    3 context sentences
    Summary · context
    Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo).
    Summary · context
    Rats were divided into 4 groups of 10 animals/group: control, 2, 12 and 18 mg/kg.
    Summary · context
    Tβ4 was administered intraperitoneally 24h after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with embolic stroke, a quartic regression model estimated 3.75 mg/kg as the optimal Tβ4 dose for neurological improvement.

    In plain wordsIn rats with stroke, a statistical model estimated the best Tβ4 dose for nerve recovery at 3.75 mg/kg.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableEstimated optimal dose for neurological improvement
    Study

    ratn = 10

    embolic middle cerebral artery occlusion (MCAo)
    Comparator
    Control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitoneal · 5 doses: 24 h after MCAo, then every 3 daysAs given in this study (rat).

    Measurements

    Estimated optimal dose
    3.75 mg/kg
    quartic regression model

    Source sentences

    Summary
    The estimated optimal dose of 3.75 mg/kg would provide optimal neurological improvement.
    3 context sentences
    Summary · context
    Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo).
    Summary · context
    Rats were divided into 4 groups of 10 animals/group: control, 2, 12 and 18 mg/kg.
    Summary · context
    Tβ4 was administered intraperitoneally 24h after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.